IRAK4

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

Retrieved on: 
Tuesday, April 9, 2024
Autoimmunity, Inflammation, Patient, SAN, STAT6, Cancer, Therapy, IRAK4, BTK

SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced today an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6). STAT6 is a key drug target in type 2 inflammation.

Key Points: 
  • “STAT6 is a key transcription factor within the IL-4/IL-13 signaling pathways which act as drivers of inflammation in allergic conditions.
  • “Preclinical data from our STAT6 degraders show that targeted degradation of this key transcription factor provides a rapidly acting and potent blockade of signaling.
  • “We are very excited to pursue our collaboration with Sanofi, as it further demonstrates the productivity of our long-standing research program to develop a pipeline of breakthrough degraders to treat inflammation and autoimmunity.
  • Nurix’s disclosed pipeline in inflammation and autoimmunity now includes the STAT6 degrader with Sanofi, the IRAK4 degrader with Gilead, and Nurix’s proprietary BTK degrader, NX-5948.

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Retrieved on: 
Tuesday, April 2, 2024
Therapy, Patient, SAN, Gilead Sciences, Research, Rheumatoid arthritis, Cancer, IRAK4, Inflammation, Pharmaceutical industry

SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gilead Sciences has elected to extend the research term of the companies’ ongoing collaboration, originally established in 2019, by an additional two years.

Key Points: 
  • “Gilead’s extension of the research period of this agreement is a testament to the productivity of our collaboration to date.
  • Most importantly, it increases the opportunity for additional clinical candidates and associated milestones to emerge from our work together with the Gilead team,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix.
  • Gilead has an option to license drug candidates resulting from the work, and Nurix retains co-development and co-detail options on up to two programs in the United States, subject to certain restrictions.
  • Upon signing the agreement in 2019, Gilead made an upfront payment of $45.0 million.

Press Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology

Retrieved on: 
Thursday, December 7, 2023
IRAK4, Dupilumab, Atopic dermatitis, Potential, RSV, Multiple sclerosis, COPD, Research and development, Vaccine, Chronic obstructive pulmonary disease, Asthma, Acne, Growth, Ambition, Webcast, Patient, Development, Fine chemical

Today Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.

Key Points: 
  • Today Sanofi is hosting an Investor R&D Event in New York providing updates and insight into its innovative pipeline and new growth drivers.
  • Sanofi will also share its ambitions to break efficacy ceilings and expand into new indications, generating a steady flow of predominantly wholly-owned new assets.
  • Vaccines - Sanofi reiterates its expectation to generate over €10 billion of annual sales by 2030, including the recent launch of Beyfortus®.
  • With an unprecedented number of potential blockbuster assets in our pipeline, we will showcase how we become a development-driven, tech-powered biopharma company, committed to serving patients and accelerating growth.

Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine

Retrieved on: 
Monday, November 13, 2023
Safety, Therapy, SAD, Clinical trial, Sanofi, Fed, Patient, Inflammation, Pharmacokinetics, Atopic dermatitis, HS, Blood, Venereology, Biomarker, Hidradenitis suppurativa, Skin, Manuscript, TPD, Pharmaceutical industry, HV, IRAK4, Dermatology, Nature Medicine

WATERTOWN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that results from the positive Phase 1 clinical trial from its lead program, KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader, were published in Nature Medicine. The results showed a reduction of disease-relevant inflammatory biomarkers in the blood and skin of HS and AD patients associated with improvement in skin lesions and symptoms. The full manuscript, “IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial,” was published online on November 13, 2023, on the Nature Medicine website.

Key Points: 
  • The results showed a reduction of disease-relevant inflammatory biomarkers in the blood and skin of HS and AD patients associated with improvement in skin lesions and symptoms.
  • The full manuscript, “IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial,” was published online on November 13, 2023, on the Nature Medicine website.
  • The Company previously reported Phase 1 results in December 2022 and at the European Academy of Dermatology and Venereology Symposium in May 2023.
  • The publication also highlights preclinical data on KT-474, including the first publication of the compound’s chemical structure.

Odyssey Therapeutics to Present Data for Three Immunology Programs at American College of Rheumatology Convergence 2023

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Managed Care, Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Odyssey, American College, TNFR2, IRAK4, Poster, Biology, RIPK2, Autoimmune disease, American College of Rheumatology, Inflammation, Therapy, Patient, ACR, Pharmaceutical industry, Regulatory T cell

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, will present data highlighting three of its immunology programs at the American College of Rheumatology ( ACR ) Convergence 2023 meeting in San Diego, California, November 10-15, 2023.

Key Points: 
  • Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, will present data highlighting three of its immunology programs at the American College of Rheumatology ( ACR ) Convergence 2023 meeting in San Diego, California, November 10-15, 2023.
  • Odyssey’s oral and poster presentations will unveil the first public data for three novel therapeutic approaches to treat large populations with underserved inflammatory and autoimmune diseases.
  • “Odyssey’s team of expert drug hunters are tirelessly working to pioneer groundbreaking therapeutic strategies for the management of autoimmune disease,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics.
  • “At ACR, we’ll give patients, researchers and investors the first look at our RIPK2 and IRAK4 scaffolding inhibitors, as well as TNFR2 agonist for Treg cell modulation.

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 2, 2023
First grade, Research, HS, AD, PD, Food, Safety, Dana–Farber Cancer Institute, Disease, Abstract, Immunology, Cutaneous T-cell lymphoma, Uveal melanoma, STAT3, International, Physician, GDF15, Webcast, Atopic dermatitis, Therapy, Investment, CTCL, Patient, Administration, Cash, Plasma, Lymphoma, Conference, IRAK4, Development, TPD, ASH, Growth, DL2, Hypotension, DL, Solar cycle 4, Arm, AACR, Thrombocytopenia, Fast Track, PTCL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, Society, SD, Hidradenitis suppurativa, MDM2, Recurrence, Blood, Peripheral T-cell lymphoma, Neutropenia, AML, Merkel-cell carcinoma, Pharmaceutical industry, Vaccine, Fine chemical, Medical device, Angela Merkel, Sanofi, Black Majesty

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the third quarter ended September 30, 2023, and provided business updates on its pipeline of protein degraders.
  • Collaboration Revenues: Collaboration revenues were $4.7 million for the third quarter of 2023 compared to $9.6 million for the third quarter of 2022.
  • Net Loss: Net loss was $52.9 million for the third quarter of 2023 compared to a net loss of $43.0 million for the third quarter of 2022.
  • Cash and Cash Equivalents: As of September 30, 2023, Kymera had $435 million in cash, cash equivalents, and investments.

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

Retrieved on: 
Friday, October 27, 2023
Mevalonate pathway, AD, Inflammation, International development, Doctor of Philosophy, Protein, TPD, Pharmacokinetics, Hidradenitis suppurativa, Sanofi, Safety, Therapy, Patient, Pharmaceutical industry, HS, MD, IRAK4

The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS.

Key Points: 
  • The Phase 2 study will evaluate the efficacy, safety, pharmacokinetics, and biological effects of KT-474 compared with placebo in adult patients with moderate to severe HS.
  • Kymera’s partner Sanofi is conducting the Phase 2 study in HS, and has initiated a second randomized Phase 2 trial in AD.
  • Under the terms of the collaboration, dosing of the first patient in the HS trial generated a milestone payment of $40 million.
  • Dosing of the first patient in the AD trial will also generate a milestone payment to Kymera.

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, October 12, 2023
Investment, Antibody, Calendar, Drug development, Research, Lymphoid leukemia, Mantle cell lymphoma, Therapy, IND, Casitas, Safety, Chronic lymphocytic leukemia, Lymphoma, Rheumatoid arthritis, FDA, DLBCL, MCL, Information technology, Clinical trial, Gilead Sciences, Paclitaxel, CLL, BTK, Bone marrow, Inflammation, Patient, Pharmaceutical industry, Vaccine, Cryptocurrency, IRAK4, Seagen, Sanofi

SAN FRANCISCO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended August 31, 2023, and provided a corporate update.

Key Points: 
  • Nurix also retains an option for U.S. profit sharing and co-promotion on two products arising from the collaboration.
  • In addition, Nurix expects to define a dose for the Phase 1b cohort expansion in the second half of 2023.
  • Nurix anticipates presenting additional clinical results from this ongoing trial in the second half of 2023.
  • Cash, cash equivalents and marketable securities was $268.7 million as of August 31, 2023, compared to $308.6 million as of May 31, 2023.

Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan

Retrieved on: 
Wednesday, September 27, 2023
IRAK4, PALO, Atopic dermatitis, Inflammation, MRGPRX2, Investigational New Drug, Patient, Standard of care, Immune-mediated inflammatory diseases, AD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Disease, Pharmaceutical industry

PALO ALTO, Calif., Sept. 27, 2023 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into a strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Japan. Under the terms of the agreement, Evommune is eligible to receive up to $60 million in upfront and customary milestone payments. In addition, Evommune is eligible to receive meaningful royalties on future sales of EVO756 in Japan.

Key Points: 
  • Under the terms of the agreement, Evommune is eligible to receive up to $60 million in upfront and customary milestone payments.
  • In addition, Evommune is eligible to receive meaningful royalties on future sales of EVO756 in Japan.
  • "We are thrilled to enter into this collaboration with Maruho, a globally respected organization that has developed and commercialized pharmaceuticals in Japan for over 100 years.
  • We believe that this is the start of a long term, multifaceted relationship between Evommune and Maruho, with the potential to accelerate development and access to EVO756 for patients in Japan and around the world."

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Thursday, July 13, 2023
CLL, Lymphoma, Gilead Sciences, AACR, Central nervous system, Chronic lymphocytic leukemia, Information technology, Lymphoid leukemia, DLBCL, ICML, Calendar, Disclosure, Clinical trial, American Association for Cancer Research, Research, BTK, CNS, Casitas, American Chemical Society, International Conference on Emerging Infectious Diseases, Patient, Investment, Mantle cell lymphoma, SAN, Paclitaxel, Bone marrow, MCL, Neoplasm, FDA, Therapy, IND, Conference, Rheumatoid arthritis, Inflammation, Pharmaceutical industry, Cryptocurrency, Vaccine, IRAK4, Sanofi

SAN FRANCISCO, July 13, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today reported financial results for the fiscal quarter ended May 31, 2023, and provided a corporate update.

Key Points: 
  • Nurix also presented preclinical data demonstrating the potential utility of NX-5948 in addressing the unmet need in patients with central nervous system (CNS) lymphoma.
  • Nurix anticipates presenting additional clinical results from this ongoing trial in the second half of 2023.
  • Nurix also anticipates defining a regulatory strategy for NX-2127 in the second half of 2023 based on emerging clinical data and feedback from the FDA.
  • Cash, cash equivalents and marketable securities was $308.6 million as of May 31, 2023, compared to $325.6 million as of February 28, 2023.